FBC
IBRX icon

Fairfield, Bush & Co’s ImmunityBio IBRX Stock Holding History

Fairfield, Bush & Co’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-30
Closed – – 261
2022
Q2 		$0 Buy
+30
New +$120 ﹤0.01% 478

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Fairfield, Bush & Co's IBRX Position: Q3 2022 in Review

Fairfield, Bush & Co sold out of ImmunityBio (IBRX) in Q3 2022, closing a stake of 30 shares.

Fairfield, Bush & Co first reported a position in IBRX in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 126 funds tracked by Wall St. Rank hold IBRX as of Q3 2022.

  • Fairfield, Bush & Co reported no remaining ImmunityBio position as of Q3 2022 after selling out during the quarter.
  • Fairfield, Bush & Co sold 30 ImmunityBio shares in Q3 2022.
  • Fairfield, Bush & Co first reported a position in ImmunityBio in Q2 2022 and held it in 1 quarter.
  • Fairfield, Bush & Co's ImmunityBio position peaked at $0 in Q2 2022.
  • 126 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2022.

Based on Fairfield, Bush & Co's 13F filing for Q3 2022, filed 7 Nov 2022.